Skip to content

The significance and indications of surgeryfor synchronous liver metastases from pancreatic cancer

The significance and indications of surgeryfor synchronous liver metastases from pancreatic cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500101837
Enrollment
Unknown
Registered
2025-04-30
Start date
2025-05-01
Completion date
Unknown
Last updated
2025-05-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic cancer with liver metastasis

Interventions

Foresight:None

Sponsors

China-Japan Friendship Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1.Age 18-75 years old; 2.Pancreatic cancer was diagnosed as pancreatic ductal adenocarcinoma by biopsy of primary/metastases; 3.Physical Condition Score (ECOG)0-1; 4.Simultaneous/prior discovery of liver metastases and primary lesions was defined as simultaneous liver metastases; 5.Enhanced CT/MRI can detect liver metastases (if the diseases not detected by enhanced CT/MRI during screening are not included in the number calculation); 6.the patient's liver, kidney and bone marrow function is good;

Exclusion criteria

Exclusion criteria: 1.The primary lesions of pancreatic cancer are acinar cell carcinoma of pancreas, neuroendocrine carcinoma of pancreas and other pathological types; 2.There are other metastases outside the liver; 3.Had other malignant tumors within 5 years; 4.History of central nervous system disease, mental illness, unstable angina pectoris, congestive heart failure, severe arrhythmia and other serious diseases; 5.Active or chronic hepatitis B/C virus infection; 6.Allergy to iodine, unable to perform enhanced imaging; 7.Anti-tumor therapy for pancreatic cancer (surgery/radiotherapy/chemotherapy/ablation); Systemic treatment included Targeted therapy, immunotherapy; 8.Female patients who are pregnant or lactating; 9.There were other conditions deemed by the investigator to be inappropriate for enrollment;

Design outcomes

Primary

MeasureTime frame
Overall Survival;

Secondary

MeasureTime frame
Recurrence free survival, RFS;

Countries

China

Contacts

Public ContactYang Zhi Ying

China-Japan Friendship Hospital

yangzhy@aliyun.com+86 10 8420 5208

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026